



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/070,439	05/30/2002	Koji Murakami	220902US01PCT	9220
22850	7590	12/24/2003	EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			MCKENZIE, THOMAS C	
			ART UNIT	PAPER NUMBER
			1624	

DATE MAILED: 12/24/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Interview Summary</b>	<b>Application No.</b> 10/070,439	<b>Applicant(s)</b> MURAKAMI ET AL.	
	<b>Examiner</b> Thomas McKenzie Ph.D.	<b>Art Unit</b> 1624	

All participants (applicant, applicant's representative, PTO personnel):

(1) Thomas McKenzie Ph.D. (3) \_\_\_\_\_

(2) Daniel Pereira, Ph.D. (4) \_\_\_\_\_

Date of Interview: 17 December 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.  
If Yes, brief description: \_\_\_\_\_

Claim(s) discussed: 5 and 6.

Identification of prior art discussed: none.


Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The enablement rejection made in point #5 of the previous office action was discussed. Applicants pointed to pages 5 and 6 of the specification concerning use of antagonists and diabetes treatment. The meaning of this passage and its relevance to clinical treatment was not readily apparent. There seemed to be a discrepancy between diabetes and obesity treatment with PPAR receptor antagonists. Treatment of both diseases is in the claims discussed. If Applicants can explain how a compound which blocks the PPAR receptor can treat a disease for which compounds which activate that same PPAR receptor are art-recognized as useful, then the rejection will be withdrawn.